New Releases from NCBI BookshelfDurvalumab (Imfinzi), Carboplatin, Paclitaxel: Therapeutic area: Endometrial cancer that is mismatch repair deficient (dMMR): Reimbursement Review [Internet].Durvalumab (Imfinzi), Carboplatin, Paclitaxel: Therapeutic area: Endometrial cancer that is mismatch repair deficient (dMMR): Reimbursement Review [Internet].

By admin / December 30, 2025

Post Content

New Releases from NCBI BookshelfBelantamab Mafodotin, Pomalidomide, Dexamethasone: Indication: Belantamab mafodotin is indicated, in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide: Reimbursement Recommendation [Internet].Belantamab Mafodotin, Pomalidomide, Dexamethasone: Indication: Belantamab mafodotin is indicated, in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide: Reimbursement Recommendation [Internet].

New Releases from NCBI BookshelfDurvalumab (Imfinzi) and Tremelimumab (Imjudo): Therapeutic area: Metastatic non–small cell lung cancer (NSCLC): Reimbursement Review [Internet].Durvalumab (Imfinzi) and Tremelimumab (Imjudo): Therapeutic area: Metastatic non–small cell lung cancer (NSCLC): Reimbursement Review [Internet].

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top

Leave a Comment Cancel Reply

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.